These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 8673495)

  • 41. Clinical and pathologic evidence of corticobasal degeneration and progressive supranuclear palsy in familial tauopathy.
    Tuite PJ; Clark HB; Bergeron C; Bower M; St George-Hyslop P; Mateva V; Anderson J; Knopman DS
    Arch Neurol; 2005 Sep; 62(9):1453-7. PubMed ID: 16157754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy.
    Katsuse O; Iseki E; Arai T; Akiyama H; Togo T; Uchikado H; Kato M; de Silva R; Lees A; Kosaka K
    Acta Neuropathol; 2003 Sep; 106(3):251-60. PubMed ID: 12802605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
    Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R
    Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autonomous design of artificial neural networks by Neurex.
    Michaud F; Gonzales Rubio R
    Neural Comput; 1996 Nov; 8(8):1767-86. PubMed ID: 8888617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
    Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
    J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Progressive supranuclear palsy].
    Nakamura T; Imai H
    Nihon Rinsho; 1997 Jan; 55(1):127-30. PubMed ID: 9014435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP.
    Josephs KA; Petersen RC; Knopman DS; Boeve BF; Whitwell JL; Duffy JR; Parisi JE; Dickson DW
    Neurology; 2006 Jan; 66(1):41-8. PubMed ID: 16401843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [An autopsy case of postencephalitic parkinsonism: investigation on neurofibrillary tangles in comparison with those in progressive supranuclear palsy].
    Mori H; Yoshimura M; Mizutani T; Kuzuhara S; Yamanouchi H; Shimada H; Tomonaga M
    No To Shinkei; 1990 Jun; 42(6):553-9. PubMed ID: 2169789
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discrepancy between clinical and pathological diagnoses of CBD and PSP.
    Mizuno T; Shiga K; Nakata Y; Nagura J; Nakase T; Ueda Y; Takanashi Y; Urasaki K; Oyamada Y; Fushiki S; Nishikawa J; Yasuhara M; Nakajima K; Nakagawa M
    J Neurol; 2005 Jun; 252(6):687-97. PubMed ID: 15754090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mixing pro- and antisaccades in patients with parkinsonian syndromes.
    Rivaud-Péchoux S; Vidailhet M; Brandel JP; Gaymard B
    Brain; 2007 Jan; 130(Pt 1):256-64. PubMed ID: 17124191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonmotor Features in Atypical Parkinsonism.
    Bhatia KP; Stamelou M
    Int Rev Neurobiol; 2017; 134():1285-1301. PubMed ID: 28805573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration.
    Bergeron C; Pollanen MS; Weyer L; Lang AE
    J Neuropathol Exp Neurol; 1997 Jun; 56(6):726-34. PubMed ID: 9184663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuropathology of variants of progressive supranuclear palsy.
    Dickson DW; Ahmed Z; Algom AA; Tsuboi Y; Josephs KA
    Curr Opin Neurol; 2010 Aug; 23(4):394-400. PubMed ID: 20610990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?
    Williams DR; Lees AJ
    Mov Disord; 2010 Feb; 25(3):357-62. PubMed ID: 20108379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy.
    Wenning GK; Colosimo C
    Rev Neurol (Paris); 2010 Oct; 166(10):829-33. PubMed ID: 20813385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Typical or atypical progressive supranuclear palsy: a comparative clinicopathologic study of three Chinese cases.
    Zhu MW; Liu J; Arzberger T; Wang LN; Wang ZF
    Int J Clin Exp Pathol; 2015; 8(1):867-74. PubMed ID: 25755788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Neuroimaging features in progressive supranuclear palsy and corticobasal degeneration].
    Mori E
    Rinsho Shinkeigaku; 2002 Nov; 42(11):1158-61. PubMed ID: 12784693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
    Tedeschi G; Litvan I; Bonavita S; Bertolino A; Lundbom N; Patronas NJ; Hallett M
    Brain; 1997 Sep; 120 ( Pt 9)():1541-52. PubMed ID: 9313638
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progressive supranuclear palsy and corticobasal degeneration.
    Litvan I
    Baillieres Clin Neurol; 1997 Apr; 6(1):167-85. PubMed ID: 9426874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience.
    Dowell JA; Hussain A; Devane J; Young D
    J Pharm Sci; 1999 Jan; 88(1):154-60. PubMed ID: 9874718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.